These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29278613)

  • 21. The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?
    Sauvageau C; Gilca V; Donken R; Fan SY; Ogilvie G; Dobson S
    Vaccine; 2019 Nov; 37(49):7203-7206. PubMed ID: 31648910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
    Rotstein Grein IH; Pinto NF; Lobo A; Groot N; Sztajnbok F; da Silva CAA; Paim Marques LB; Appenzeller S; Islabão AG; Magalhães CS; de Almeida RG; Bica B; Fraga M; da Fraga ACM; Dos Santos MC; Robazzi T; Terreri MTR; Bandeira M; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi G
    Lupus; 2020 Jul; 29(8):934-942. PubMed ID: 32501172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age.
    Wen T; Xu X; Pan C; Hu S; Zhao H; Zhang X; Qiao Y; Zhao F
    Hum Vaccin Immunother; 2024 Dec; 20(1):2412391. PubMed ID: 39390947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
    Murata S; Takeuchi Y; Yamanaka K; Hayakawa J; Yoshida M; Yokokawa R; Wakana A; Sawata M; Tanaka Y
    Jpn J Infect Dis; 2019 Sep; 72(5):299-305. PubMed ID: 31155600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males.
    Wu RF; Zimmerman RK; Lin CJ
    Hum Vaccin Immunother; 2017 Mar; 13(3):676-679. PubMed ID: 27682819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
    Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
    Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
    Kahn JA; Xu J; Kapogiannis BG; Sleasman JW
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):241-245. PubMed ID: 28291048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
    Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus.
    Mok CC; Ho LY; To CH
    Vaccine; 2018 May; 36(23):3301-3307. PubMed ID: 29699792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
    Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
    Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
    Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
    Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.
    Levin MJ; Moscicki AB; Song LY; Fenton T; Meyer WA; Read JS; Handelsman EL; Nowak B; Sattler CA; Saah A; Radley DR; Esser MT; Weinberg A;
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):197-204. PubMed ID: 20574412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV9: Combating HPV-associated cancers by strengthening serotype defenses.
    Dougherty SA; Hayney MS
    J Am Pharm Assoc (2003); 2015; 55(6):670-672. PubMed ID: 26547601
    [No Abstract]   [Full Text] [Related]  

  • 37. Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults.
    Rainone V; Giacomet V; Penagini F; Fabiano V; Calascibetta F; Mameli C; Pisanelli S; Zuccotti GV; Clerici M; Trabattoni D
    AIDS; 2015 Mar; 29(6):739-43. PubMed ID: 25849837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
    Vichnin M; Bonanni P; Klein NP; Garland SM; Block SL; Kjaer SK; Sings HL; Perez G; Haupt RM; Saah AJ; Lievano F; Velicer C; Drury R; Kuter BJ
    Pediatr Infect Dis J; 2015 Sep; 34(9):983-91. PubMed ID: 26107345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.